Toxicity of psychotropic drugs in patients with COVID-19: A systematic review

Sabe, Michel; Dorsaz, Orianne France; Huguelet, Philippe; Kaiser, Stefan

doi:10.1016/j.genhosppsych.2021.02.006

Scientific article

Review

English

Toxicity of psychotropic drugs in patients with COVID-19: A systematic review

ContributorsSabe, Michel; Dorsaz, Orianne France; Huguelet, Philippe; Kaiser, Stefan

Published inGeneral Hospital Psychiatry, vol. 70, p. 1-9

Publication date2021

Abstract

Due to the global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We aimed to review clinical evidence regarding the potential toxicity of psychiatric medications in the context of SARS-CoV-2 infection.

Keywords

SARS-CoV-2
COVID-19
Toxicity
Psychotropic drugs
Clozapine
Lithium
Valproic acid

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de psychiatrie

Research groups

Psychopathologie clinique et expérimentale (987)

Citation (ISO format)

SABE, Michel et al. Toxicity of psychotropic drugs in patients with COVID-19: A systematic review. In: General Hospital Psychiatry, 2021, vol. 70, p. 1–9. doi: 10.1016/j.genhosppsych.2021.02.006

Article (Published version)

CC BY

Appendix

Identifiers

PID : unige:150324
DOI : 10.1016/j.genhosppsych.2021.02.006
PMID : 33631694

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S0163834321000268

Journal ISSN0163-8343

319views

1445downloads

Creation03/03/2021 11:50:00

First validation03/03/2021 11:50:00

Update13/10/2025 16:30:37

Status update16/03/2023 00:14:26

Last indexation11/02/2026 10:52:58

Archive ouverte UNIGE

Toxicity of psychotropic drugs in patients with COVID-19: A systematic review

Due to the global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We aimed to review clinical evidence regarding the potential toxicity of psychiatric medications in the context of SARS-CoV-2 infection.

Technical informations